{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2008"],"condition":["Colorectal cancer metastatic","METASTATIC COLORECTAL CANCER PATIENTS"],"disease":["Metastatic Colorectal Cancer Patients","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2542918"],"location":["Italy"],"study_start_month":["1"],"keyword":["CAMPTO","AVASTIN","Oxaliplatin","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB","description":"Primary objectives: To compare the progression-free-survival of second-line chemotherapy with Bevacizumab to second-line chemotherapy alone in patients treated with first-line chemotherapy + Bevacizumab.\nPrimary endpoints: progression-free-survival","dates":{"creation":"2008-01-15"},"accession":"2542918","cross_references":{"EU Clinical Trials Register":["2007-002886-11"]}}